Loading
IARC estimates 15,108 new cancer cases and 8,932 cancer deaths in Bosnia and Herzegovina in 2024; the commonest new cancers are trachea, bronchus and lung, colorectum and breast. This page is assembled automatically from OnCo's data: 12 trials with a site there, and says what OnCo does not yet hold.
| Site | New cases | Rate | OnCo page |
|---|---|---|---|
| Trachea, bronchus and lung | 2,493 | 33.1 | Lung cancer (all types), Non-small-cell lung cancer, Small-cell lung cancer |
| Colorectum | 2,318 | 30.0 | Colorectal cancer |
| Breast | 1,440 | 42.4 | Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer, HER2-positive breast cancer |
| Prostate | 996 | 27.4 | Prostate cancer |
| Bladder | 730 | 9.3 | Bladder & urothelial cancer |
| Stomach | 697 | 9.2 | Gastric & gastro-oesophageal junction cancer |
| Pancreas | 621 | 7.5 | Pancreatic ductal adenocarcinoma |
| Liver and intrahepatic bile ducts | 520 | 6.4 | Hepatocellular carcinoma |
| Brain, central nervous system | 396 | 6.7 | Glioma & glioblastoma |
| Non-Hodgkin lymphoma | 339 | 6.1 | Non-Hodgkin lymphoma (all types), Diffuse large B-cell lymphoma |
| Site | Deaths | Rate | OnCo page |
|---|---|---|---|
| Trachea, bronchus and lung | 2,119 | 27.6 | Lung cancer (all types), Non-small-cell lung cancer, Small-cell lung cancer |
| Colorectum | 1,123 | 13.1 | Colorectal cancer |
| Breast | 583 | 13.9 | Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer, HER2-positive breast cancer |
| Stomach | 542 | 6.8 | Gastric & gastro-oesophageal junction cancer |
| Pancreas | 500 | 6.0 | Pancreatic ductal adenocarcinoma |
| Liver and intrahepatic bile ducts | 476 | 5.6 | Hepatocellular carcinoma |
| Prostate | 464 | 11.9 | Prostate cancer |
| Brain, central nervous system | 349 | 5.2 | Glioma & glioblastoma |
| Bladder | 279 | 3.0 | Bladder & urothelial cancer |
| Leukaemia | 213 | 2.6 | Acute myeloid leukaemia, Acute lymphoblastic leukaemia, Chronic lymphocytic leukaemia |
| Trial | Lead sponsor | ||||
|---|---|---|---|---|---|
| Phase 3 | Recruiting | Grifols Therapeutics LLC | 62 | 2026-09-30 | |
| Phase 3 | Recruiting | Can-Fite BioPharma | 32 | 2025-04-29 | |
| Phase 3 | Active not recruiting | mAbxience Research S.L. | 173 | 2026-09-10 | |
ALINA NCT03456076 | Phase 3 | Active not recruiting | Hoffmann-La Roche | 114 | 2026-07-15 |
| Phase 3 | Active not recruiting | Samsung Bioepis Co., Ltd. | 93 | 2026-07-07 | |
lidERA NCT04961996 | Phase 3 | Active not recruiting | Hoffmann-La Roche | 622 | 2026-06-17 |
ALEX NCT02075840 | Phase 3 | Completed | Hoffmann-La Roche | 97 | 2026-05-29 |
| Phase 3 | Active not recruiting | Amgen | 180 | 2026-01-12 | |
IMpassion130 NCT02425891 | Phase 3 | Completed | Hoffmann-La Roche | 247 | 2022-07-19 |
AURELIA NCT00976911 | Phase 3 | Completed | Hoffmann-La Roche | 117 | 2022-06-21 |
STEVIE (vismodegib in ordinary practice) NCT01367665 | Phase 2 | Completed | Hoffmann-La Roche | 181 | 2019-06-06 |
EORTC 22922/10925 NCT00002851 | Phase 3 | Unknown | European Organisation for Research and Treatment of Cancer - EORTC | 48 | 2010-01-29 |
Trial records in OnCo whose ClinicalTrials.gov entry lists at least one site in Bosnia and Herzegovina, captured 2026-10-07 to 2026-10-07. Recruiting first, then the most recently updated. The status is the study's overall status; whether a site in Bosnia and Herzegovina is open is on the registry page, under Contacts and Locations.
OnCo holds no institution, company or person in Bosnia and Herzegovina.
OnCo records approvals for United States, European Union, United Kingdom, Japan, China, Australia and India. Bosnia and Herzegovina is not one of them, so no approval in OnCo speaks for it. See the approvals by region matrix for what is held.
Bosnia and Herzegovina is not among the 60 countries ranked in the country coverage queue (November 2026), which ranks countries without a page by cases, deaths, research output and population. Know a source? Suggest an edit.